Last reviewed · How we verify

NCT03912961: SC-DRAI

The Santa Cruz Diabetic Retinopathy Utilizing Artificial Intelligence Study

Completed Last updated 5 June 2020
What this trial tests

trial testing Picture of the retina with a handheld retinal camera in Diabetic Retinopathy in 1,034 participants. Completed in 15 October 2019.

Timeline
21 January 2019
Primary endpoint
14 April 2019
15 October 2019

Quick facts

Lead sponsorRetina Global
StatusCompleted
Study typeOBSERVATIONAL
Enrollment1,034
Start date21 January 2019
Primary completion14 April 2019
Estimated completion15 October 2019
Sites3 locations across Bolivia

Drugs / interventions tested

Conditions studied

Sponsor

Retina Global

Who can join

18 and older, any sex, with Diabetic Retinopathy. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

In this clinical trial, we plan to evaluate the usefulness of artificial intelligence (AI) software paired with a handheld retinal camera to compare diabetic retinopathy status in Bolivian patients as read by retina specialists versus the AI software.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Diabetic Retinopathy

Currently open trials in the same condition.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03912961.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing